Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310169 | 0.92 | IGF1R (0.83) | IGF1RCDK2EGFRKCNH2CYP3A4 | |
| SCHEMBL2345579 | 0.90 | IGF1R (0.84) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL13362109 | 0.88 | IGF1R (0.75) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL3314030 | 0.88 | IGF1R (0.85) | IGF1RCDK2EGFRKCNH2CYP3A4 | |
| SCHEMBL3378394 | 0.86 | IGF1R (0.84) | IGF1RCDK2EGFRKCNH2CYP3A4 | |
| SCHEMBL2365358 | 0.86 | IGF1R (0.84) | IGF1RCDK2EGFRKCNH2CYP3A4 | |
| SCHEMBL2361496 | 0.86 | IGF1R (0.84) | IGF1RCDK2EGFRKCNH2CYP3A4 | |
| SCHEMBL3344728 | 0.85 | IGF1R (0.83) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL2347439 | 0.84 | IGF1R (0.80) | IGF1RCDK2EGFRKCNH2 | |
| SCHEMBL3314176 | 0.84 | IGF1R (1.00) | IGF1RCDK2EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | claimed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | claimed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | IGF1R 4384/4885CDK2 64/4885EGFR 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.